Christian Jackisch

Christian Jackisch

UNVERIFIED PROFILE

Are you Christian Jackisch?   Register this Author

Register author
Christian Jackisch

Christian Jackisch

Publications by authors named "Christian Jackisch"

Are you Christian Jackisch?   Register this Author

100Publications

4910Reads

21Profile Views

Overcoming endocrine resistance in neoadjuvant endocrine therapy for early breast cancer.

Lancet Oncol 2019 Sep 8;20(9):1185-1187. Epub 2019 Aug 8.

Sana Hospital Offenbach, Department of Obsterics and Gynecology and Breast Cancer Center, Offenbach, D-63069 Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30500-5DOI Listing
September 2019

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

N Engl J Med 2019 02 5;380(7):617-628. Epub 2018 Dec 5.

From the German Breast Group, Neu-Isenburg (G.M., S.L., H.H.F., P.W.), the Center for Hematology and Oncology Bethanien, Frankfurt (S.L.), the AGO-B and HELIOS Klinikum Berlin-Buch, Berlin (M.U.), the National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg (A.S.), Evangelische Kliniken Gelsenkirchen, Gelsenkirchen (H.H.F.), the Arbeitsgemeinschaft Gynäkologische Onkologie - Breast and Sana Klinikum Offenbach, Offenbach (C.J.), the Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen (P.A.F.), and Mammazentrum Hamburg am Krankenhaus Jerusalem, Hamburg (P.W.) - all in Germany; the National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-S.H.); Instituto do Câncer do Estado de São Paulo, São Paulo (M.S.M.); the National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation and Orlando Health University of Florida Health Cancer Center, Orlando (E.P.M.); the NSABP Foundation and Allegheny Health Network Cancer Institute (N.W.) and the NSABP Foundation and University of Pittsburgh Cancer Institute, School of Medicine (P.R.), Pittsburgh; Hospital Universitario La Paz-Instituto de Investigación Hospital Universitario La Paz, Madrid (A.R.); Institut Régional du Cancer de Montpellier, Université de Montpellier, INSERM Unité 1194, Montpellier, France (W.J.); the NSABP Foundation and Providence Portland Medical Center, Portland, OR (A.K.C.); the National Cancer Institute, Mexico City (C.A.-S.); the NSABP Foundation and Stanford University School of Medicine, Stanford (I.L.W.), and Genentech, South San Francisco (L.H.L., D.T., M.S., S.M.S.) - both in California; Yale University School of Medicine, Yale Cancer Center, and Smilow Cancer Hospital, New Haven, CT (M.P.D.); the Ireland Cooperative Oncology Research Group, Dublin (J.P.C.); Fudan University Shanghai Cancer Center (Z.S.) and Roche (China) Holding (H.W.), Shanghai; the Cancer Center Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy (E.R.C.); F. Hoffmann-La Roche, Welwyn Garden City, United Kingdom (H.D.); and the NSABP Foundation and Virginia Commonwealth University Massey Cancer Center, Richmond (C.E.G.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1814017
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1814017DOI Listing
February 2019

Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?

Cancer Manag Res 2018 8;10:5423-5431. Epub 2018 Nov 8.

Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S177240DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235000PMC
November 2018

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer.

Authors:
Achim Wöckel Jasmin Festl Tanja Stüber Katharina Brust Mathias Krockenberger Peter U Heuschmann Steffi Jírů-Hillmann Ute-Susann Albert Wilfried Budach Markus Follmann Wolfgang Janni Ina Kopp Rolf Kreienberg Thorsten Kühn Thomas Langer Monika Nothacker Anton Scharl Ingrid Schreer Hartmut Link Jutta Engel Tanja Fehm Joachim Weis Anja Welt Anke Steckelberg Petra Feyer Klaus König Andrea Hahne Traudl Baumgartner Hans H Kreipe Wolfram Trudo Knoefel Michael Denkinger Sara Brucker Diana Lüftner Christian Kubisch Christina Gerlach Annette Lebeau Friederike Siedentopf Cordula Petersen Hans Helge Bartsch Rüdiger Schulz-Wendtland Markus Hahn Volker Hanf Markus Müller-Schimpfle Ulla Henscher Renza Roncarati Alexander Katalinic Christoph Heitmann Christoph Honegger Kerstin Paradies Vesna Bjelic-Radisic Friedrich Degenhardt Frederik Wenz Oliver Rick Dieter Hölzel Matthias Zaiss Gudrun Kemper Volker Budach Carsten Denkert Bernd Gerber Hans Tesch Susanne Hirsmüller Hans-Peter Sinn Jürgen Dunst Karsten Münstedt Ulrich Bick Eva Fallenberg Reina Tholen Roswita Hung Freerk Baumann Matthias W Beckmann Jens Blohmer Peter Fasching Michael P Lux Nadia Harbeck Peyman Hadji Hans Hauner Sylvia Heywang-Köbrunner Jens Huober Jutta Hübner Christian Jackisch Sibylle Loibl Hans-Jürgen Lück Gunter von Minckwitz Volker Möbus Volkmar Müller Ute Nöthlings Marcus Schmidt Rita Schmutzler Andreas Schneeweiss Florian Schütz Elmar Stickeler Christoph Thomssen Michael Untch Simone Wesselmann Arno Bücker Andreas Buck Stephanie Stangl

Geburtshilfe Frauenheilkd 2018 Nov 26;78(11):1056-1088. Epub 2018 Nov 26.

Institut für Klinische Epidemiologie und Biometrie (IKE-B), Universität Würzburg, Würzburg, Germany.

View Article

Download full-text PDF

Source
http://www.thieme-connect.de/DOI/DOI?10.1055/a-0646-4630
Publisher Site
http://dx.doi.org/10.1055/a-0646-4630DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261741PMC
November 2018

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer.

Geburtshilfe Frauenheilkd 2018 Oct 19;78(10):927-948. Epub 2018 Oct 19.

Universitätsfrauenklinik Würzburg, Universität Würzburg, Würzburg, Germany.

View Article

Download full-text PDF

Source
http://www.thieme-connect.de/DOI/DOI?10.1055/a-0646-4522
Publisher Site
http://dx.doi.org/10.1055/a-0646-4522DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202580PMC
October 2018

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2018.

Breast Care (Basel) 2018 07 15;13(3):196-208. Epub 2018 Jun 15.

Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Ulm, Ulm, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000489329DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062659PMC
July 2018

Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).

J Clin Oncol 2018 05 15;36(13):1308-1316. Epub 2018 Mar 15.

Michael Untch, Helios-Klinikum, Berlin-Buch; Jens-Uwe Blohmer, St Gertrauden Krankenhaus, Berlin; Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Bernd Gerber, Universitäts-Frauenklinik, Rostock; Christian Schem, Mammazentrum am Krankenhaus Jerusalem, Hamburg; Mahdi Rezai, Luisenkrankenhaus; Tanja Fehm, Universitäts-Frauenklinik, Düsseldorf; Peter A. Fasching, Universitätsklinikum Erlangen, Erlangen; Hans Tesch, Hämatologisch-Onkologische Gemeinschaftspraxis am Agaplesion Bethanien Krankenhaus; Christine Solbach, Universitäts-Klinikum, Frankfurt; Holm Eggemann, Universitäts-Frauenklinik, Magdeburg; Claus Hanusch, Klinikum zum Roten Kreuz, München; Christian Jackisch, Sana Klinikum Offenbach, Offenbach am Main; Georg Kunz, Klinik für Gynäkologie und Geburtshilfe, Dortmund; Maik Hauschild, Gesundheitszentrum Fricktal, Rheinfelden; and Jens Huober, Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Ulm, Ulm, Germany.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.75.9175
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.75.9175DOI Listing
May 2018

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2017.

Breast Care (Basel) 2017 Jul 21;12(3):172-183. Epub 2017 Jun 21.

Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Ulm, Ulm, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000477575DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527197PMC
July 2017

Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars.

Breast 2017 Apr 23;32:199-216. Epub 2017 Feb 23.

Pfizer Inc., 235 East 42nd Street, New York, NY 10017-5755, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2017.01.010DOI Listing
April 2017

Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial.

J Natl Cancer Inst 2016 08 20;108(8). Epub 2016 Apr 20.

Department of Medicine, Breast European Adjuvant Study Team (BrEAST) Data Centre, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium (AS, EdA, MP, HAAJr); Frontier Science (Scotland) Ltd, Grampian View, Kincraig, Kingussie, UK (DAt, IB, CC); Novartis Pharmaceuticals Corporation, East Hanover, NJ (YH); Alliance Statistics and Data Center, Mayo Clinic, Section of Biostatistics, Scottsdale, AZ (ACD); Sunnybrook Odette Cancer Centre, the University of Toronto and the NCIC Clinical Trials Group, Toronto, Ontario, Canada (KIP); The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD (ACW); Sana Klinikum Offenbach, Offenbach, Germany (CJ); National Institute of Oncology, Budapest, Hungary (IL); Helios Klinikum Berlin-Buch, Berlin, Germany (MU); Royal Marsden Hospital NHS Trust, Sutton/Surrey, UK (IS); Patricia Ritchie Centre for Cancer Care and Research, The University of Sydney, Mater Hospital, North Sydney, Australia (FB); Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China (BX); Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru (HG); Mayo Clinic, Jacksonville, FL (EAP)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw037DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017935PMC
August 2016

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

J Clin Oncol 2016 Apr 23;34(10):1034-42. Epub 2015 Nov 23.

Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.1797DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872016PMC
April 2016

Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy.

Eur J Cancer 2016 Jan 13;53:65-74. Epub 2015 Dec 13.

Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg, Im Neuenheimer Feld 460, 69120 Heidelberg, Germany; Universitäts-Frauenklinik Heidelberg, Im Neuenheimer Feld 440, 69120 Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.09.022DOI Listing
January 2016

Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience.

Breast Cancer Res Treat 2016 Jan 26;155(1):127-32. Epub 2015 Dec 26.

Department of Biostatistics and Computational Biology, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health, Harvard Medical School, Boston, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007%2Fs10549-015-36
Web Search
http://link.springer.com/10.1007/s10549-015-3656-0
Publisher Site
http://dx.doi.org/10.1007/s10549-015-3656-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947530PMC
January 2016

Neoadjuvant breast cancer treatment as a sensitive setting for trastuzumab biosimilar development and extrapolation.

Future Oncol 2015 ;11(1):61-71

Department of Obstetrics & Gynecology, Breast Cancer Center, Gynecologic Cancer Center, Sana Klinikum Offenbach, Starkenburgring 66, 63069 Offenbach, Germany.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon.14.187
Publisher Site
http://dx.doi.org/10.2217/fon.14.187DOI Listing
September 2015

The Treatment of Primary Breast Cancer in Older Women With Adjuvant Therapy: A Retrospective Analysis of Data From Over 3000 Patients From the PATH Biobank, With Two-Year Follow-up.

Dtsch Arztebl Int 2015 Aug;112(35-36):577-84

Institute of Social Medicine and Epidemiology, University Medical Center, Lübeck, PATH Biobank, Augsburg, Department of Obstetrics and Gynecology, Sana Klinikum Offenbach, Department of Obstetrics and Gynecology, Klinikum Kassel, Department of Obstetrics and Gynecology, St. Johannes Hospital, Dortmund, Institute for Cancer Epidemiology e.V., University of Lübeck.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3238/arztebl.2015.0577DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4577665PMC
August 2015

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

J Clin Oncol 2015 Mar 22;33(9):983-91. Epub 2014 Dec 22.

Carsten Denkert, Bruno V. Sinn, Berit M. Pfitzner, Wolfgang D. Schmitt, Silvia Darb-Esfahan, Stephan Wienert, Frederick Klauschen, and Manfred Dietel, Charité Universitätsmedizin Berlin; Carsten Denkert, German Cancer Consortium (DKTK); Peter Klare, Praxisklinik and Breast Center; Jens-Uwe Blohmer, St Gertrauden Krankenhaus and Charité Universitätsmedizin; Micheal Untch, Helios Klinikum Berlin-Buch, Berlin; Gunter von Minckwitz, Stephan Gade, Keyur Mehta, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Women's Hospital, University of Frankfurt; Hans Tesch, Bethanien Hospital, Frankfurt; Jan C. Brase, Ralf Kronenwett, Karin Fisch, and Kristin Krappmann, Sividon Diagnostics, Cologne; Ralf Kronenwett, Heinrich-Heine University Düsseldorf, Düsseldorf; Christian Schem, Christian-Albrechts Universität zu Kiel, Kiel; Christoph Salat, Onkologische Schwerpunktpraxis, Munich; Marcus Schmidt, Johannes-Gutenberg Universität Mainz, Mainz; Sherko Kümmel, Kliniken Essen-Mitte, Essen; Peter Sinn, University of Heidelberg, Heidelberg; Christian Jakisch and Sibylle Loibl, Sana Klinikum Offenbach, Offenbach; Toralf Reimer, Klinikum Südstadt, Rostock, Germany; Sherene Loi, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia; Sherene Loi and Christos Sotiriou, Institute Jules Bordet, Brussels, Belgium; and Fabrice André, Institute Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.1967DOI Listing
March 2015

Trastuzumab in advanced breast cancer--a decade of experience in Germany.

BMC Cancer 2014 Dec 8;14:924. Epub 2014 Dec 8.

Department of Obstetrics and Gynaecology and Breast Cancer Center, Sana Klinikum Offenbach GmbH, Starkenburgring 66, D-63060 Offenbach, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-14-924DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295514PMC
December 2014

Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).

J Clin Oncol 2014 Jul 9;32(20):2159-65. Epub 2014 Jun 9.

Evandro de Azambuja and Martine J. Piccart-Genhart, Institut Jules Bordet; Evandro de Azambuja, Breast European Adjuvant Study Team; Martine J. Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Marion J. Procter and Dominique Agbor-Tarh, Frontier Science Scotland, Kincraig, Kingussie; David A. Cameron, University of Edinburgh and Western General Hospital, Edinburgh; Ian E. Smith, Royal Marsden Hospital and the Institute of Cancer Research; Mitch Dowsett, the Royal Marsden National Health Service Trust, London, United Kingdom; Dirk J. van Veldhuisen, University of Groningen, Groningen, the Netherlands; Otto Metzger-Filho and Richard D. Gelber, Dana-Farber Cancer Institute, Boston, MA; Jutta Steinseifer, F. Hoffmann-La Roche, Basel; Thomas M. Suter, Swiss Cardiovascular Center, Inselspital, Bern University Hospital, Bern, Switzerland; Michael Untch, HELIOS Klinikum Berlin, Buch; Christian Jackisch, Klinikum Offenbach, Offenbach, Germany; Luca Gianni, San Raffaele Institute, Milan, Italy; Jose Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Richard Bell, Andrew Love Cancer Centre, Geelong Hospital, Geelong, Australia; and Brian Leyland-Jones, Edith Sanford Breast Cancer Research Institute, Sioux Falls, SD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.9288DOI Listing
July 2014

Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer.

Expert Rev Anticancer Ther 2014 May 28;14(5):511-21. Epub 2014 Feb 28.

Medical Oncology Department, Breast Cancer Unit, Hospital Universitario, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.2014.883922DOI Listing
May 2014

Optimal Sequencing of Anti-HER2 Therapy.

Breast Care (Basel) 2014 May;9(2):138-40

Klinik für Innere Medizin I, Universitätskliniken der Medizinischen Universität Wien, Austria.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s40265-013-0118
Web Search
http://www.karger.com?doi=10.1159/000362300
Publisher Site
http://dx.doi.org/10.1159/000362300DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038308PMC
May 2014

Adverse event management of oral mucositis in patients with breast cancer.

Breast Care (Basel) 2014 Apr;9(4):232-7

Department of Obstetrics and Gynaecology, Breast Cancer Center, Offenbach, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000366246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209263PMC
April 2014

Response.

J Natl Cancer Inst 2014 Mar 28;106(3):djt452. Epub 2014 Feb 28.

Affiliations of authors: Department of Gynecology and Obstetrics, Klinikum Frankfurt Höchst, Frankfurt, Germany (VM); Department of Gynecology and Obstetrics, Klinikum Offenbach GmbH, Offenbach, Germany (CJ); National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany (AS); Department of Gynecology and Obstetrics, University of Duesseldorf, Duesseldorf, Germany (JH); Gynäkologisch-Onkologische Praxis Hannover, Hannover, Germany (H-JL); Department of Gynecology and Gynecologic Oncology, KEM Hussenstift, Essen, Germany (AdB); Department of Gynecology, University of Halle, Halle (Saale), Germany (CT); Medizinisches Zentrum Bonn-Friedensplatz, Bonn, Germany (CK); Department of Gynecology and Obstetrics, University of Bonn, Bonn, Germany (WK); Ev. Krankenhaus Bethesda, Brustzentrum Niederrhein, Mönchengladbach, Germany (UAN); Department of Gynecology and Obstetrics, University of Jena, Jena, Germany (IBR); WiSP Research Institute, Langenfeld, Germany (AH); Department of Gynecology and Obstetrics, University of Ulm, Ulm, Germany (RK); Department of Gynecology and Obstetrics, Helios Klinikum Berlin-Buch, Berlin, Germany (MU).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt452DOI Listing
March 2014

Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.

J Clin Oncol 2013 12 18;31(36):4504-11. Epub 2013 Nov 18.

Jose Baselga, Memorial Sloan-Kettering Cancer Center, NY; James G. Greger Jr, GlaxoSmithKline, Collegeville, PA; Hatem A. Azim Jr, Martine Piccart, Evandro de Azambuja, BrEAST Data Centre, Institut Jules Bordet, Université Libre de Bruxelles; Phuong Dinh, Breast International Group, Brussels; Peter Vuylsteke, Sint-Elisabeth Hospital, Namur, Belgium; Dominique Agbor-tarh, Ian Bradbury, Frontier Science, Kincraig, Kingussie, Scotland; Ian Smith, Royal Marsden Hospital, and Institute of Cancer Research, London, United Kingdom; Serena Di Cosimo, IRCCS Fondazione Instituto Nazionale dei Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Christian Jackisch, Kilinikum Offenbach, Offenbach; Bahriye Aktas, Kliniken Essen-Mitte, Evang, Essen; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Sung-Bae Kim, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Chiun-Sheng Huang, National Taiwan University Hospital; Ruey Kuen Hsieh, Mackey Memorial Hospital, Taipei, Taiwan; and Lydia Dreosti, University of Pretoria, Pretoria, South Africa.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.50.9448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5795667PMC
December 2013

German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.

J Clin Oncol 2013 Oct 26;31(28):3531-9. Epub 2013 Aug 26.

Gunter von Minckwitz, Valentina Nekljudova, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Volker Möbus, Klinikum Frankfurt-Hoechst, Frankfurt; Andreas Schneeweiss, National Center for Tumor Diseases Heidelberg, Heidelberg; Jens Huober, University Hospital Düsseldorf, Düsseldorf; Christoph Thomssen, University Hospital Halle an der Saale, Halle an der Saale; Michael Untch, Helios Klinikum Berlin Buch, Berlin; Christian Jackisch, Klinikum Offenbach, Offenbach; Ingo J. Diel, Schwerpunktpraxis für gynäkologische Onkologie, Mannheim; Dirk Elling, Sana Klinikum Lichtenberg, Lichtenberg; Bettina Conrad, Frauenklinik, Kassel; Rolf Kreienberg, University Hospital Ulm, Ulm; Volkmar Müller, University Hospital Hamburg, Hamburg; Hans-Joachim Lück, Praxis Hannover; Stefanie Noeding, Nordstadt Krankenhaus, Hannover; Ingo Bauerfeind, Frauenklinik Landshut, Landshut; Michael Clemens, Klinikum Trier, Trier; Marcus Schmidt, University Hospital Mainz, Mainz; Helmut Forstbauer, Haematologic-Oncologic Praxis, Troisdorf; Jana Barinoff, Klinikum Mitte, Essen; Antje Belau, University Hospital, Greifswald; and Nadia Harbeck, Universität München, München, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.47.2167DOI Listing
October 2013

Response-guided neoadjuvant chemotherapy for breast cancer.

J Clin Oncol 2013 Oct 3;31(29):3623-30. Epub 2013 Sep 3.

Gunter von Minckwitz, Keyur Mehta, and Sibylle Loibl, Headquarters, German Breast Group, Neu-Isenburg; Jens Uwe Blohmer, St Gertrauden Krankenhaus, Berlin); Serban Dan Costa, Universitäts-Frauenklinik, Magdeburg; Carsten Denkert, Institute for Pathology, Charite, Berlin; Holger Eidtmann, Universitäts-Frauenklink, Kiel; Wolfgang Eiermann and Claus Hanusch, Klinikum zum Roten Kreuz, Munich; Bernd Gerber, Universitäts-Frauenklinik, Rostock; Jörn Hilfrich, Henrietten-Stiftung, Hanover; Jens Huober, Universitäts-Frauenklinik Tübingen, Frauenklinik; Christian Jakisch and Sibylle Loibl, Städtische Kliniken, Offenbach; Gunter von Minckwitz, Universitäts-Frauenklinik, Frankfurt; Sherko Kümmel, Klinikum Essen Mitte, Essen; Stefan Paepke, Universitäts-Frauenklinik rechts der Isar, Munich; Andreas Schneeweiss, National Center for Tumor Diseases, University of Heidelberg; Michael Untch, Helios-Klinikum, Berlin-Buch; Dirk Michael Zahm, Brustzentrum Stiftung Rehabilitation Heidelberg (SRH) Waldkliniken, Gera, Germany; Jens Huober, Kantonsspital, St Gallen, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.45.0940DOI Listing
October 2013

Comparing guidelines for adjuvant endocrine therapy in postmenopausal women with breast cancer: a coming of age.

Expert Rev Anticancer Ther 2011 Feb;11(2):277-86

Department of Obstetrics and Gynecology and Breast Cancer Center, Klinikum Offenbach GmbH, Starkenburgring 66, D-63069 Offenbach, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.10.218DOI Listing
February 2011

Systemic Therapy for Women with ErbB2-Positive Breast Cancer: New Options, New Challenges.

Breast Care (Basel) 2010;5(s1):1-2. Epub 2010 Apr 26.

Department of Obstetrics and Gynecology and Breast Cancer Center, Klinikum Offenbach.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000285707DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2931092PMC
April 2010

Future Roles of Lapatinib in ErbB2-Positive Breast Cancer: Adjuvant and Neoadjuvant Trials.

Breast Care (Basel) 2010;5(s1):22-24. Epub 2010 Apr 26.

Department of Obstetrics, Universitätsfrauenklinik Magdeburg, Halle/Saale, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000285778DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2931097PMC
April 2010

News from the San Antonio Breast Cancer Symposium 2009.

Breast Care (Basel) 2010 Mar 16;5(1):38-43. Epub 2010 Feb 16.

Clinic for Gynecology, Gynecologic Oncology and Obstetrics, Breast Cancer Center, Academic Hospital of the University Charite Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000283284DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357166PMC
March 2010